Go Deep
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,154 | -5.7 | 1.73 | 0.08 | 941.86 |
| Oct 2026 | 21,168 | -5.6 | 1.72 | 0.08 | 934.28 |
| Oct 2026 | 21,089 | -5.8 | 1.77 | 0.08 | 961.01 |
| Oct 2026 | 21,196 | -5.6 | 1.71 | 0.08 | 922.52 |
| Oct 2026 | 20,937 | -6.1 | 1.87 | 0.08 | 1,010.74 |
| Oct 2026 | 20,739 | -6.5 | 1.99 | 0.08 | 1,077.11 |
| Oct 2026 | 20,779 | -6.4 | 1.96 | 0.08 | 1,061.21 |
| Oct 2026 | 20,810 | -6.3 | 1.95 | 0.08 | 1,048.68 |
Monte Rosa Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 8,968,000.0 | 4,210,000.0 | 2,781,000.0 | 12,768,000.0 |
| Net Profit | -43,397,000.0 | -44,503,000.0 | -46,135,000.0 | -27,081,000.0 |
| EPS | -0.5 | -0.5 | -0.7 | -0.4 |
Monte Rosa Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 123,672,000.0 | 75,622,000.0 | 0.0 | 0.0 | — |
| Net Profit | -38,626,000.0 | -72,700,000.0 | -135,352,000.0 | -108,501,000.0 | — |
| EPS | -0.6 | -1.2 | -2.6 | -2.3 | — |
Monte Rosa Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 448,659,000.0 | 438,732,000.0 | 303,755,000.0 | 342,389,000.0 | — |
| Total Liabilities | 215,603,000.0 | 215,796,000.0 | 124,505,000.0 | 70,976,000.0 | — |
| Total Equity | 233,056,000.0 | 222,936,000.0 | 179,250,000.0 | 271,413,000.0 | — |
Owes vs Owns
Monte Rosa Therapeutics, Inc. owed $0.29 for every $1 it owned in Jun 2026, up from $0.21 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.48× | 0.49× | 0.41× | 0.21× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Monte Rosa Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 84.1%Receivables 2.6%Fixed assets (tangible) 11.2%Other assets 2.1%
How it's funded — Dec 2025
Short-term debt 1.0%Long-term debt 7.8%Payables 0.8%Other liabilities 38.5%Shareholders' equity 51.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 377.1 | 372.1 | 232.4 | 262.8 |
| Receivables | 11.6 | 0.2 | 0.5 | 7.7 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 50.4 | 56.3 | 62.6 | 61.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.6 | 10.1 | 8.2 | 10.0 |
| Liabilities & equity | ||||
| Short-term debt | 4.4 | 3.7 | 3.2 | 3.1 |
| Long-term debt | 34.8 | 39.0 | 42.9 | 43.9 |
| Payables | 3.5 | 17.2 | 11.2 | 7.9 |
| Other liabilities | 172.9 | 155.9 | 67.3 | 16.1 |
| Shareholders' equity | 233.1 | 222.9 | 179.2 | 271.4 |
| Net tangible assets | 233.1 | 222.9 | 179.2 | 271.4 |
Monte Rosa Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -22,798,000.0 | 41,996,000.0 | -43,802,000.0 | -92,466,000.0 | — |
| Investing Activities | -101,833,000.0 | -44,452,000.0 | 88,801,000.0 | -219,219,000.0 | — |
| Financing Activities | 30,351,000.0 | 98,892,000.0 | 27,492,000.0 | 20,466,000.0 | — |